Breaking News Instant updates and real-time market news.

VRTX

Vertex

$165.71

-2.97 (-1.76%)

16:29
05/20/19
05/20
16:29
05/20/19
16:29

Vertex initiated with an Outperform at Credit Suisse

Credit Suisse analyst Evan Seigerman started Vertex Pharmaceuticals with an Outperform rating and $209 price target. The analyst also names Vertex his top large-cap pick in U.S. Biotechnology. The company has a "differentiated growth profile" that should not only drive near-term cash flows, but also allow reinvestment in the business to support longer-term growth, Seigerman tells investors in a research note. He sees continued commercial execution, pipeline updates and guidance updates supporting the shares relative to peers.

  • 05

    Jun

VRTX Vertex
$165.71

-2.97 (-1.76%)

03/26/19
03/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Strong Buy from Market Perform at Raymond James , to Hold from Sell at Loop Capital, and to Sector Weight from Underweight at KeyBanc. 2. BB&T (BBT) upgraded to Buy from Hold at Deutsche Bank with analyst Matt O'Connor saying after meeting with CEO of SunTrust (STI), he remains positive on the merger and the combined stock. 3. Vertex (VRTX) upgraded to Outperform from Market Perform at William Blair with analyst Y. Katherine Xu citing expectations that the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. 4. Allegiant Travel (ALGT) upgraded to Outperform from Neutral at Macquarie with analyst Susan Donofrio citing her meetings with its management last week. 5. TransAlta (TAC) upgraded to Buy from Hold at TD Securities with analyst John Mould saying Brookfield Renewable Partners (BEP) $750M investment in TransAlta improves the company's financial flexibility, accelerates its ability to return capital to shareholders and advance the coal-to-gas conversion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/19
EVER
04/11/19
INITIATION
Target $183
EVER
In Line
Vertex initiated with an In Line at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Vertex with an In-Line rating and a price target of $183. The analyst says the company has "great science, execution, and management", but its multiple is the highest relative to its peers and appears to be "priced to perfection". Mehrotra adds that the debate around EU pricing will intensify, becoming a "bigger and longer headwind".
04/16/19
PIPR
04/16/19
NO CHANGE
Target $75
PIPR
Overweight
Piper reiterates $75 target for Crispr after CTX001 gets Fast Track
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Crispr Therapeutics after the company and partner Vertex (VRTX) announced Fast Track Designation for CTX001 to treat transfusion-dependent beta thalassemia. The analyst believes Crispr's ex vivo approach and biological rational of targeting fetal hemoglobin "de-risk and differentiate" CTX001 from other gene editing players. And he continues to think that first-in-man CTX001 data this year "will serve as an important driver" for Crispr and the gene editing field. Tenthoff says Crispr Therapeutics remains a top for 2019.
05/15/19
PIPR
05/15/19
NO CHANGE
Target $217
PIPR
Overweight
Piper Jaffray bullish on Vertex following protein degradation partnership
Piper Jaffray analyst Edward Tenthoff notes that Vertex has partnered with private protein degradation company Kymera for $70M upfront and up to $1B in potential milestones. Vertex is diversifying outside of Cystic Fibrosis in order to generate the next leg of long-term growth, he notes. The analyst is confident in the FDA and EMA approval of Vertex's game-changing TripleRx in 2020 following NDA filing in Q3 and OUS by year end 2019. Tenthoff projects total CF sales will grow from $3.52B this year to $4.51B in 2020 with TripleRx launch. He reiterates an Overweight rating and $217 price target on the shares.

TODAY'S FREE FLY STORIES

VTR

Ventas

$68.60

-0.01 (-0.01%)

07:13
06/19/19
06/19
07:13
06/19/19
07:13
Recommendations
Ventas analyst commentary  »

Ventas price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$3.69

0.06 (1.65%)

07:13
06/19/19
06/19
07:13
06/19/19
07:13
Hot Stocks
Sorrento Therapeutics says Phase 1b resiniferatoxin trial met day 84 goals »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$68.60

-0.01 (-0.01%)

07:13
06/19/19
06/19
07:13
06/19/19
07:13
Hot Stocks
Ventas Investor Day presentation sees 'core portfolio growth' through 2024 »

Sees 5%-7% FFO and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USCR

U.S. Concrete

$47.49

-0.78 (-1.62%)

07:13
06/19/19
06/19
07:13
06/19/19
07:13
Conference/Events
U.S. Concrete management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 13

    Nov

FCAU

Fiat Chrysler

$13.49

0.11 (0.82%)

07:12
06/19/19
06/19
07:12
06/19/19
07:12
Initiation
Fiat Chrysler initiated  »

Fiat Chrysler reinstated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

NCMI

National CineMedia

$6.44

-0.03 (-0.46%)

07:11
06/19/19
06/19
07:11
06/19/19
07:11
Upgrade
National CineMedia rating change  »

National CineMedia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

MDB

MongoDB

$166.49

1.27 (0.77%)

07:11
06/19/19
06/19
07:11
06/19/19
07:11
Recommendations
MongoDB analyst commentary  »

MongoDB bulls likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

AXTA

Axalta Coating

$25.82

0.03 (0.12%)

07:10
06/19/19
06/19
07:10
06/19/19
07:10
Hot Stocks
Axalta Coating up 14% after announcing review of strategic alternatives »

In pre-market trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:10
06/19/19
06/19
07:10
06/19/19
07:10
General news
FX Update: The dollar has seen moderate softness »

FX Update: The dollar has…

NBRV

Nabriva Therapeutics

$2.11

0.045 (2.18%)

07:09
06/19/19
06/19
07:09
06/19/19
07:09
Hot Stocks
Nabriva Therapeutics submits Type A Meeting Request to FDA for CONTEPO »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

ADBE

Adobe

$276.80

1.21 (0.44%)

07:09
06/19/19
06/19
07:09
06/19/19
07:09
Upgrade
Adobe rating change  »

Adobe upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$3.69

0.06 (1.65%)

07:08
06/19/19
06/19
07:08
06/19/19
07:08
Hot Stocks
Sorrento Therapeutics CEO to provide updates on CD38 immunotherapies »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTEC

Intec Pharma

$4.78

-0.02 (-0.42%)

07:07
06/19/19
06/19
07:07
06/19/19
07:07
Hot Stocks
Intec Pharma's Accordion Pill meets primary endpoint in PK study »

Intec Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$1.82

0.13 (7.69%)

07:07
06/19/19
06/19
07:07
06/19/19
07:07
Initiation
KemPharm initiated  »

KemPharm initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCRB

Seres Therapeutics

$2.61

0.16 (6.53%)

07:06
06/19/19
06/19
07:06
06/19/19
07:06
Hot Stocks
Seres Therapeutics provides statement regarding FDA safety alert for FMT use »

Seres Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$276.80

1.21 (0.44%)

07:06
06/19/19
06/19
07:06
06/19/19
07:06
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$60.46

1.205 (2.03%)

07:04
06/19/19
06/19
07:04
06/19/19
07:04
Hot Stocks
Cubic announces sale of commercial properties in San Diego, Orlando for $46M »

Cubic announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYX

Systemax

$20.56

0.16 (0.78%)

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Conference/Events
Systemax management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 25

    Sep

PLXP

PLx Pharma

$4.93

-0.07 (-1.40%)

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Hot Stocks
PLx Pharma says 'on track' to file VAZALORE submission by year-end »

PLx Pharma announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDB

MongoDB

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Recommendations
MongoDB analyst commentary  »

MongoDB price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

SMLP

Summit Midstream

$6.90

0.13 (1.92%)

07:03
06/19/19
06/19
07:03
06/19/19
07:03
Downgrade
Summit Midstream rating change  »

Summit Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PT

Pintec Technology

$4.38

-0.04 (-0.90%)

07:02
06/19/19
06/19
07:02
06/19/19
07:02
Hot Stocks
Pintec Technology expands partnership with 1an.com »

Pintec Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:02
06/19/19
06/19
07:02
06/19/19
07:02
General news
MBA Mortgage Applications Composite Index data reported »

Week of 6/14 MBA Mortgage…

CTLT

Catalent

$50.48

-0.1 (-0.20%)

, BMY

Bristol-Myers

$47.79

-0.42 (-0.87%)

07:02
06/19/19
06/19
07:02
06/19/19
07:02
Hot Stocks
Catalent tu purchase Bristol-Myers' manufacturing facility in Italy »

Catalent (CTLT) has…

CTLT

Catalent

$50.48

-0.1 (-0.20%)

BMY

Bristol-Myers

$47.79

-0.42 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 16

    Sep

AXTA

Axalta Coating

$25.82

0.03 (0.12%)

07:02
06/19/19
06/19
07:02
06/19/19
07:02
Hot Stocks
Axalta Coating initiates review of strategic alternatives »

Axalta Coating announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.